Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 8:15 a.m. PST / 11:15 a.m. EST. An audio webcast will be available on the company's website, with a replay accessible one hour after the event for 21 days. Seres is pioneering microbiome therapeutics, with its SER-109 program showing positive pivotal clinical results for treating C. difficile infections and receiving Breakthrough Therapy and Orphan Drug designations. The company is also advancing SER-155 in a Phase 1b study to protect against infections in stem cell transplant patients.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 a.m. PST / 11:15 a.m. EST.

An audio webcast of the presentation will be available under the “Investors and News” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced to prevent further recurrences of C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.

For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005104/en/

PR Contact

Kristin Ainsworth

kainsworth@serestherapeutics.com

IR Contact

Carlo Tanzi, Ph.D.

ctanzi@serestherapeutics.com

Source: Seres Therapeutics, Inc.

FAQ

When will Seres Therapeutics present at the J.P. Morgan Healthcare Conference?

Seres Therapeutics will present on January 12, 2023, at 8:15 a.m. PST / 11:15 a.m. EST.

Where can I listen to the Seres Therapeutics presentation?

The presentation can be listened to via an audio webcast available on the Seres Therapeutics website.

What is the SER-109 program by Seres Therapeutics?

The SER-109 program aims to prevent further recurrences of C. difficile infection and has achieved positive pivotal clinical results.

What designations has the SER-109 program received?

The SER-109 program has received Breakthrough Therapy and Orphan Drug designations from the FDA.

What is the focus of SER-155 in development by Seres Therapeutics?

SER-155 is being evaluated in a Phase 1b study to reduce infections in patients receiving allogeneic hematopoietic stem cell transplantation.